AI-Enhanced Low-Dose CT Screening for Early Detection of Pancreatic Cancer in Adults 50 and Older

What this Trial Is About

Pancreatic ductal adenocarcinoma PDAC is a highly aggressive cancer with a low 5-year survival rate, making early diagnosis vital to improving outcomes. Current screening methods are limited and often miss early-stage disease, especially for the general public. Researchers are evaluating the use of an Artificial Intelligence AI system called PANDA combined with low-dose computed tomography LDCT to enhance pancreatic cancer screening in a prospective, multicenter, observational cohort, aiming to improve early detection and reduce unnecessary procedures. Participants will undergo annual LDCT scans analyzed by the PANDA AI system. Abnormal findings identified by the AI are reviewed by a multidisciplinary team MDT to decide next steps suspected pancreatic cancer or precursor lesions lead to hospital examinations benign lesions receive personalized monitoring and cases confirmed as normal by MDT will have at least one year of follow-up. If abnormalities appear during follow-up, participants will be managed accordingly. This approach focuses on evaluating detection rates, predictive values, consensus, and recall rates over two years. During the study, participants will complete LDCT exams and consent to follow-up assessments based on AI and MDT findings. Researchers will monitor pancreatic cancer detection rates, early-stage cancer proportions, and safety indicators like false positives and unnecessary invasive procedures. Follow-up will continue for at least one year for some participants, with ongoing monitoring to assess the effectiveness and safety of AI-assisted LDCT screening in a health check-up population.

Artificial Intelligence-powered Low-Dose Computed Tomography for Screening of Pancreatic Cancer